DUBLIN, November 29, 2021--(BUSINESS WIRE)--The "Congestive Heart Failure (CHF) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
This 'Congestive Heart Failure (CHF) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the HF, historical and forecasted epidemiology as well as the HF trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Congestive Heart Failure (CHF) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of HF, Diagnosed Prevalent Population of HF, Gender-specific diagnosed prevalent cases of HF, Age-specific diagnosed prevalent cases of HF, Type-specific diagnosed prevalent cases of HF, NYHA class-specific diagnosed prevalent cases of HF, Diagnosed prevalent cases of HF with Ejection Fraction, Diagnosed Prevalent cases of HF associated with comorbidities scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.
Total Diagnosed Prevalent Cases of Heart Failure (HF) in the 7MM was found to be 12,602,028 in 2020, which is expected to grow during the study period (2018-2030).
Among 7MM, the United States has the highest diagnosed prevalent population of HF, i.e., 5,163,119 cases in 2020, which is 40.97% of the total diagnosed cases of HF in the 7MM.
In EU-5, Germany has the highest number of diagnosed cases, i.e., 2,216,497 followed by Spain with 1,283,827 cases and Italy with 1,164,031 cases. While, UK has the least number of cases with 728,547 in 2020.
There are several Heart Failure related comorbidities which include obesity, hyperlipidemia, metabolic syndrome, and others. Amongst them in the US, in 2020, 3,837,746, 2,237,179, 991,319, 1,626,382, 1,587,659, 3,097,871, and 2,065,247 cases were observed in Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Atrial Fibrillation, COPD, Ischemic heart disease, and Dilated cardiomyopathy.
Age-specific diagnosed prevalent cases are seen maximum in the age group of 75-84 (1,607,918) and lowest in < 44 (155,410) in 2020, this is due to the progressive aging of the population as well as improved and better survival after cardiac insults, such as myocardial infarction, especially in developed countries.
In 2020, the estimated cases of HFpEF (HFmEF) and HFrEF in the US were 3,097,871 and 2,065,247 which is expected to increase by 2030.
In 2020, New York Heart Association (NYHA) Classification is comprised of class I (No symptoms and no limitation in ordinary physical activity), class II (Mild symptoms and slight limitation during ordinary activity), class III (Marked limitation in activity due to symptoms, even during less than ordinary activity), and class IV (Severe limitations) cases which were estimated to be 2,633,191, 1,512,794, 516,312, and 516,312 cases, in the US.
In 2020, the estimated cases of acute heart failure and chronic heart failure in US were 1,548,936 and 3,614,183, respectively.
Heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age. According to the analysis, in 2020, the estimated cases of HF were 2,478,297 in males and 2,684,822 in females, in the US.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. SWOT Analysis
6. Congestive Heart Failure (CHF) Market Overview at a Glance
6.1. Market Share (%) Distribution of CHF by therapies in 2021
6.2. Market Share (%) Distribution of CHF by therapies in 2030
7. Disease Background and Overview
7.2. Causes of HF
7.3. Signs and Symptoms
7.4. Stages of HF
7.5. Classification of HF
7.6. Common pathophysiologic mechanisms in HF
7.8. Diagnostic Tests
7.9. Differential Diagnosis
8.1. Angiotensin-converting enzyme (ACE) inhibitors
8.2. Angiotensin II receptor blockers (ARBs)
8.3. Mineralocorticoid receptor antagonists (MRAs)
8.4. If-Channel Inhibitor
8.6. Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
8.8. Digoxin (Lanoxin)
8.9. Hydralazine and isosorbide dinitrate
8.12. Dual Antiplatelet Therapy (DAPT)
8.13. Unique characteristics of heart failure treatment in Japan
8.14. Non-pharmacological intervention and lifestyle modification
9. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management (2017)
9.1. Key Recommendations for Practice
9.2. Recommendations on Treatment
10. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2021)
10.1. Guidelines for Diagnosis
10.2. Guidelines for Patients with Heart Failure With Reduced Ejection Fraction (HRrEF)
10.3. Guidelines for Cardiac Rhythm Management for Heart Failure with Reduced Ejection Fraction
10.4. Guidelines for Patients with Heart Failure With Mildly Reduced Ejection Fraction (HRmrEF)
10.5. Guidelines for Patients with Heart Failure With Preserved Ejection Fraction (HRpEF)
10.6. Guidelines for Multidisciplinary Team Management for the Prevention and Treatment of Chronic Heart Failure
10.7. Guidelines for Advanced Heart Failure
10.8. Guidelines for acute heart failure
10.9. Guidelines on Cardiovascular Comorbidities
11. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure (Update From 2017)
11.1. Guidelines on Pharmacologic Therapy
11.2. Guidelines on If Channel Blocker or HCN Channel Blocker; Ivabradine
11.3. Guidelines on ARNI: Sacubitril/valsartan
11.4. Guidelines on SGLT2 Inhibitors
11.5. Guidelines on Nonpharmacologic Therapy
11.6. Guidelines on Surgical Treatment
11.7. Guidelines for disease management
12. American College of Cardiology (ACC), American Heart Association (AHA), and HF Society of America (HFSA) (2021)
13. Chronic Heart Failure in Adults: Diagnosis and Management (NICE Guidelines 2018)
13.1. Guidelines on Diagnosing Heart Failure
13.2. Guidelines on Treating Heart Failure with Reduced Ejection Fraction
13.3. Guidelines on Specialist Treatment
13.4. Guidelines on treating heart failure with reduced ejection fraction in people with chronic kidney disease
13.5. Guidelines on managing all Types of Heart Failure
13.6. Guidelines on interventional procedures
14. Acute heart failure: Diagnosis And Management (NICE Guidelines 2014)
14.1. Guidelines on Diagnosis, Assessment, and Monitoring
14.2. Guidelines on Initial Pharmacological Treatment
14.3. Guidelines on Initial Nonpharmacological Treatment
14.4. Guidelines for Treatment after Stabilization
14.5. Guidelines on Valvular Surgery and Percutaneous Intervention
14.6. Guidelines on Mechanical Assist Devices
15. Epidemiology and Patient Population
15.1. Key Findings
15.2. Epidemiology Methodology
15.3. 7MM Prevalent Patient Population of Heart Failure
15.4. Total Diagnosed Prevalent Patient Population of Heart Failure in the 7MM
16. Country Wise-Epidemiology of HF
16.1. The United States
17. Organizations contributing towards CHF
18. Patient Journey
For more information about this report visit https://www.researchandmarkets.com/r/rp7xfu
View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005480/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900